New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Contributed by: Business Wire

Logo

Tags

Biotechnology

Neurology

Health

Pharmaceutical

Clinical Trials

AJOVY, Migraine Prevention, new data

More Like This

Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder

New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

PR Newswire associated0

New Study Evaluates How Quickly the Migraine Preventive Impact of Nerivio® Starts

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease